Sector
Healthcare & Life Sciences
123 published announcements name Healthcare & Life Sciences. The industry the release names.
Most recent
SEARCH ALL 123 Sidley Represents Verily Health in Investment from NVIDIA 17 Sept 2026
Hogan Lovells Cadwalader advises on US$209 million Symbiotec Pharmalab IPO 17 Sept 2026
Latham Advises on Beta Bionics’ US$150 Million Public Offering of Common Stock and Pre-Funded Warrants 17 Sept 2026
Latham & Watkins Advises Thatch on US$108 Million Series C 17 Sept 2026
Latham Represents Neuberger and KKR in Investment in Datavant Alongside New Mountain Capital 17 Sept 2026
Latham & Watkins Advises Cheplapharm on Strategic Partnership With Sanofi 17 Sept 2026
Latham Advises GSK on Agreement to Acquire a Potential Best-in-Class Trispecific T Cell-Engager 17 Sept 2026
Latham & Watkins Advises Tyra on US$400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants 17 Sept 2026
Latham Advises on Financing for Hanger and Numotion’s Combination 17 Sept 2026
Latham & Watkins Advises SEQENS on Its Financial Restructuring 17 Sept 2026
Herbert Smith Freehills Kramer advises Medcaptain on its Hong Kong IPO 8 Sept 2026
Latham & Watkins Advises PatientIQ on US$30 Million Series C 6 Sept 2026
Latham Advises Enovis on Binding Offer to Acquire eCential Robotics 6 Sept 2026
Baker McKenzie Advises McKesson on its USD 2.25 Billion Acquisition of Precision Medicine Group 28 Aug 2026
DLA Piper advises Kreg Therapeutics on financing to advance patient mobility solutions 28 Aug 2026
Sidley Represents Werewolf Therapeutics in Merger with Ambros Therapeutics and Concurrent US$150 Million Private Placement 24 Aug 2026
Latham & Watkins Advises Mountaingate Capital in Sale of Relevate Health 24 Aug 2026
Latham & Watkins Advises on Oversubscribed US$150 Million Private Placement in Connection With Werewolf Therapeutics and Ambros Therapeutics’ Reverse Merger Transaction 24 Aug 2026
Latham Advises Gossamer Bio on Up to US$250 Million Structured Private Placement, Including US$150 Million of Committed Capital 21 Aug 2026
Latham Advises KaliVir Immunotherapeutics on US$14 Million Series A Extension Financing 20 Aug 2026
Latham & Watkins Advises LEO Pharma in Acquisition of Worldwide Rights to MC1R Agonist Dersimelagon 19 Aug 2026
Latham Advises Frazier Life Sciences on Private Placement Financing in Connection With Fulcrum Therapeutics and Slate Medicines Merger 18 Aug 2026
Latham Advises on Satellos’ US$50 Million ATM Offering 18 Aug 2026
Latham Advises on MapLight Therapeutics’ US$150 Million Private Placement Financing 15 Aug 2026
Latham Represents Zentalis Pharmaceuticals in US$80.5 Million Underwritten Public Offering 15 Aug 2026
Latham & Watkins Advises CHG Healthcare in Acquisition of KREWE Anesthesia 13 Aug 2026
HSF Kramer advises SEVER Life Sciences B.V. on the sale of Nordic Group B.V. 12 Aug 2026
Global law firm Hogan Lovells Cadwalader advises Jazz Pharmaceuticals on acquisition of Actio Biosciences 12 Aug 2026
Latham Advises Medical Faculty Associates in Transaction With the George Washington University and Universal Health Services 11 Aug 2026
Latham Advises Novonesis on Acquisition of MicroBioGen 11 Aug 2026
Latham & Watkins Advises on Latigo Biotherapeutics’ Upsized US$345.6 Million Initial Public Offering 10 Aug 2026
Latham & Watkins Advises on BlossomHill Therapeutics’ Upsized US$150 Million IPO 10 Aug 2026
Latham & Watkins Advises Manipal Health Enterprises on US$973 Million IPO 10 Aug 2026
Latham & Watkins Advises Alkeus Pharmaceuticals on Acquisition by Tarsus Pharmaceuticals 10 Aug 2026
Herbert Smith Freehills Kramer advises Black Kite Partners on the successful completion of its acquisition of 13SICK, DoctorDoctor, 24-7Medcare and Australian Surgical Assisting 6 Aug 2026
Latham & Watkins Advises Perceptive Advisors on Growth Financing for Leading Oncology Biotech Autolus Therapeutics 5 Aug 2026
Latham Advises Goldman Sachs Alternatives on Investment in Numantec 4 Aug 2026
Latham & Watkins Advises CordenPharma on Acquisition of AmbioPharm 4 Aug 2026
Latham Advises GSK on US$110 Million Research Collaboration With Relation Therapeutics 3 Aug 2026
Latham Advises on Private Credit Financing for Apex Infusion’s Partnership With SkyKnight Capital 30 Jul 2026
Latham Advises on Financing for American Industrial Partners’ Completed US$1.272 Billion Acquisition of Avanos Medical, Inc. 30 Jul 2026
Latham Advises BC Partners on Its investment in InfoRLife in Partnership With ACS Dobfar 30 Jul 2026
Baker McKenzie advises on the sale of Vitabiotics to Bain Capital 28 Jul 2026
Latham Advises on Scribe Therapeutics’ US$155.51 Million IPO 28 Jul 2026
Dentons advises Biofarm and its majority shareholders on landmark acquisition by Polpharma through voluntary public takeover offer 24 Jul 2026
Latham Represents Warburg Pincus‑Led Investor Group in Investment in Paradigm Oral Health’s Surgeon‑Led Buyback 24 Jul 2026
DLA Piper advises Kira Pharmaceuticals on merger with Jasper Therapeutics 23 Jul 2026
Latham & Watkins Advises ŌURA in Investment by Lilly 23 Jul 2026
Latham Advises Crystalys Therapeutics on US$130 Million Series B Financing 23 Jul 2026
Hogan Lovells Cadwalader advises HSBC UK and HSBC Asset Management on financing Corten Capital and Ampersand’s acquisition of Beacon Intelligence 22 Jul 2026
Hogan Lovells Cadwalader advises Merz on the inaugural issuance of a €450 Million Schuldschein loan 21 Jul 2026
Latham & Watkins Advises Tempus AI on US$1.5 Billion Acquisition of Personalis 21 Jul 2026
Sidley Represents NextCure in Merger With Avere Therapeutics and Concurrent US$320 Million Private Placement 20 Jul 2026
Latham & Watkins Represents AtaiBeckley in Sale to Lilly 17 Jul 2026
Latham & Watkins Advises Bridgepoint on Acquisition of GBA Group 17 Jul 2026
Dentons advises Invenio Partners on the sale of a majority stake in Haelan healthcare to Provectus Capital Partners 16 Jul 2026
Clifford Chance advises Paragon on the sale of Primed Group to Inflexion 15 Jul 2026
Latham & Watkins Advises Erasca on US$550 Million Upsized Public Offering of Common Stock 15 Jul 2026
Latham & Watkins Advises Inflexion on the Acquisition of Primed Group 15 Jul 2026
Sidley Represents Sino Biopharm in an Exclusive License Agreement With AstraZeneca 14 Jul 2026